Recent advances in varicella-zoster virus infection

Annals of Internal Medicine

Volumn 130, Issue 11, 1999, Pages 922-932

  Cohen, Jeffrey I ^a   Brunell, Philip A ^a   Straus, Stephen E ^a   Krause, Philip R ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; HERPES ZOSTER; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

EID: 0032966715     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-11-199906010-00017     Document Type: Conference Paper

References (104)

1. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 1996;45:1-36.
2. Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, Croen KD, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med. 1988;108:221-37.
3. Cohen JI, Straus SE. Varicella-zoster virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven; 1996:2525-45.
4. Arvin AM, Moffat JF, Redman R. Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res. 1996;46:263-309.
5. Myers MG, Connelly BL. Animal models of varicella. J Infect Dis. 1992;166 (Suppl 1)S48-50.
6. Heineman TC, Cohen JI. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J Virol. 1995;69:7367-70.
7. Moffat JF, Zerboni L, Sommer MH, Heineman TC, Cohen JI, Kaneshima H, et al. The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A. 1998;95:11969-74.
8. Mahalingam R, Wellish M, Wolf W, Dueland AN, Cohrs R, Vafai A, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med. 1990;323:627-31.
9. Hyman RW, Ecker JR, Tenser RB. Varicella-zoster virus RNA in human trigeminal ganglia. Lancet. 1983;2:814-6.
10. Gilden DH, Rozenman Y, Murray R, Devlin M, Vafai A. Detection of varicella-zoster virus nucleic acid in neurons of normal human thoracic ganglia. Ann Neurol. 1987;22:377-80.
11. Croen KD, Ostrove JM, Dragovic LJ, Straus SE. Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A. 1988;85: 9773-7.
12. Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A. 1995;92:10980-4.
13. Kennedy PG, Grinfeld E, Gow JW. Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc Natl Acad Sci U S A. 1998;95:4658-62.
14. Mahalingam R, Wellish M, Cohrs R, Debrus S, Piette J, Rentier B, et al. Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci U S A. 1996;93:2122-4.
15. Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein SJ. Aberrant intracellular localization of varicella-zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A. 1998;95:7080-5.
16. Meier JL, Holman RP, Croen KD, Smialek JE, Straus SE. Varicella-zoster virus transcription in human trigeminal ganglia. Virology. 1993;193:193-200.
17. Cohrs RJ, Barbour M, Gilden DH. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol. 1996; 70:2789-96.
18. Cohen JI. Infection of cells with varicella-zoster virus down-regulates surface expression of class I major histocompatibility complex antigens. J Infect Dis. 1998;177:1390-3.
19. Sawyer MH, Chamberlin a, Wu YN, Aintablian N, Wallace MR. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J Infect Dis. 1994;169:91-4.
20. Asano Y, Iwayama S, Miyata T, Yazaki T, Ozaki T, Tsuzuki K, et al. Spread of varicella in hospitalized children having no direct contact with an indicator zoster case and its prevention by a live vaccine. Biken J. 1980; 23:157-61.
21. Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis. 1988;158:238-41.
22. Wreghitt TG, Whipp PJ, Bagnall J. Transmission of chickenpox to two intensive care unit nurses from a liver transplant patient with zoster [Letter]. J Hosp Infect. 1992;20:125-6.
23. Moore DA, Hopkins RS. Assessment of a school exclusion policy during a chickenpox outbreak. Am J Epidemiol. 1991;133:1161-7.
24. Brunell PA. Transmission of chickenpox in a school setting prior to the observed exanthem. Am J Dis Child. 1989;143:1451-2.
25. Ozaki T, Matsui Y, Asano Y, Okuno T, Yamanishi K, Takahashi M. Study of virus isolation from pharyngeal swabs in children with varicella. Am J Dis Child. 1989;143:1448-50.
26. Sawyer MH, Wu YN, Chamberlin CJ, Burgos C, Brodine SK, Bowler WA, et al. Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. J Infect Dis. 1992;166:885-8.
27. Srugo I, Israele V, Wittek AE, Courville T, Vimal VM, Brunell PA. Clinical manifestations of varicella-zoster virus infections in human immunodeficiency virus-infected children. Am J Dis Child. 1993;147:742-5.
28. Peterson CL, Vugia DJ, Meyers HB, Chao SM, Vogt J, Lanson J, et al. Risk factors for invasive group A streptococcal infections in children with varicella: a case-control study. Pediatr Infect Dis J. 1996;15:151-6.
29. Guess HA, Broughton DD, Melton LJ 3d, Kurland LT. Population-based studies of varicella complications. Pediatrics. 1986;78(4 Pt 2):723-7.
30. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994;343:1548-51.
31. Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med. 1994;330:901-5.
32. Brunell PA. Fetal and neonatal varicella-zoster infections. Semin Perinatol. 1983;7:47-56.
33. Brunell PA, Kotchmar GS Jr. Zoster in infancy: failure to maintain virus latency following intrauterine infection. J Pediatr. 1981;98:71-3.
34. Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet. 1989;2:371-3.
35. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92:223-8.
36. Abzug MJ, Cotton MF. Severe chickenpox after intranasal use of corticosteroids. J Pediatr. 1993;123:577-9.
37. Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster Arch Intern Med. 1997;157:1209-13.
38. Grossman MC Grossman ME. Chronic hyperkeratotic herpes zoster and human immunodeficiency virus infection. J Am Acad Dermatol. 1993:28(2 Pt 2):306-8.
39. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 1992;166:1153-6.
40. Stemmer SM, Kinsman K, Tellschow S, Jones RB. Fatal noncutaneous visceral infection with varicella-zoster virus in a patient with lymphoma after autologous bone marrow transplantation. Clin Infect Dis. 1993;16:497-9.
41. Manian FA, Kindred M, Fulling KH. Chronic varicella-zoster virus myelitis without cutaneous eruption in a patient with AIDS: report of a fatal case. Clin Infect Dis. 1995;21:986-8.
42. Kuppermann BD, Quiceno JI, Wiley C, Hesselink J, Hamilton R, Keefe K, et al. Clinical and histopathologic study of varicella zoster virus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1994;118:589-600.
43. Hellinger WC, Bolling JP, Smith TF, Campbell RJ. Varicella-zoster virus retinitis in a patient with AIDS-related complex: case report and brief review of the acute retinal necrosis syndrome. Clin Infect Dis. 1993;16:208-12.
44. Wallace MR, Chamberlin CJ, Zerboni L, Sawyer MH, Oldfield EC, Olson PE, et al. Reliability of a history of previous varicella infection in adults. JAMA. 1997;278:1520-2.
45. Whitley RJ, Gnann JW. Acyclovir: a decade later. N Engl J Med. 1992;327: 782-9.
46. Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335:721-9.
47. Crumpacker C. The pharmacological profile of famciclovir. Semin Dermatol. 1996;15(2 Suppl 1):14-26.
48. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996;52:754-72.
49. Kimberlin DW, Whitley RJ. Antiviral resistance: mechanisms, clinical significance, and future implications. J Antimicrob Chemother. 1996;37:403-21.
50. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev. 1997;10:674-93.
51. Snoeck R, Andrei G, de Clercq E. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999;57:187-206.
52. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, Fried RP. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med. 1978;298:981-7.
53. Whitley R, Hilty M, Haynes R, Bryson Y, Connor JD, Soong SJ, et al. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr. 1982;101:125-31.
54. Whitley RJ, Soong SJ, Dolin R, Betts R, Linnemann C Jr, Alford CA Jr. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982;307:971-5.
55. Shepp DH, Dandliker PS, Meyer JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med. 1986;314:208-12.
56. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199-226.
57. deMiranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(Suppl B):29-37.
58. Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children - a collaborative study. J Pediatr. 1982;101:622-5.
59. Vere Hodge RA. Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother. 1993;4:67-84.
60. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 1991;325:1539-44.
61. Balfour HH Jr, Rotbart HA, Feldman S, Dunkle LM, Feder HM Jr, Prober CG, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. J Pediatr. 1992;120(4 Pt 1):627-33.
62. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3d. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med. 1992;117:358-63.
63. American Academy of Pediatrics Committee on Infectious Diseases: The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics. 1993; 91:674-6.
64. Nathwani D, Maclean A, Conway S, Carrington D. Varicella infections in pregnancy and the newborn. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect. 1998;36(Suppl 1):59-71.
65. Pahwa S, Biron K, Lim W, Swenson P, Kaplan MH, Sadick N, Pahwa R. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA. 1988;260:2879-82.
66. Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, et al. Acydovir-resistant varicella-zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;112:187-91.
67. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42.
68. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
69. Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology. 1991;98:1216-29.
70. Dworkin RH, Carrington D, Cunningham A, Kost RG, Levin MJ, McKendrick MW, et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res. 1997;33:73-85.
71. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valacidovir on prolonged pain. J Infect Dis. 1998;178(Suppl 1):S81-4.
72. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed). 1986;293:1529-32.
73. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J. 1989;102:93-5.
74. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valacydovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546-53.
75. DeGreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents Chemother. 1995;4:241-6.
76. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995;123:89-96.
77. Balfour HH Jr, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother. 1983;12(Suppl B):169-79.
78. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896-900.
79. Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376-83.
80. Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis. 1998; 178(Suppl 1):S71-5.
81. Bernstein JE, Bickers DR, Dahl MV, Roshal JY. Treatment of chronic postherpetic neuralgia with topical capsaicin. A preliminary study. J Am Acad Dermatol. 1987;17:93-6.
82. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 1982;32: 671-3.
83. Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol. 1994;35(Suppl):S50-3.
84. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-42.
85. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, et al, Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics. 1993;92:219-22.
86. Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics. 1977;59:3-7.
87. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986;78(4 Ft 2):748-56.
88. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J. 1998;17:256-7.
89. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;2: 1288-90.
90. Takahashi M. Clinical overview of varicella vaccine: development and early studies. Pediatrics. 1986;78(4 Pt 2):736-41.
91. Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis. 1996; 174(Suppl3):S310-3.
92. Varivax (Varicella Virus Vaccine Live [Oka/Merck]) 52nd Physician's Desk Reference. Montvale, NJ: Medical Economics, 1998:1762-5.
93. Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr. 1995;127:518-25.
94. Recommendations for the use of live attenuated varicella vaccine. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 1995; 95:791-6.
95. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infec Dis J. 1992;11:19-23.
96. Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics. 1993;92:833-7.
97. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med. 1991;325:1545-50.
98. Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics. 1986;77:53-6.
99. LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis. 1996;174(Suppl 3):S320-3.
100. Brunell PA, Geiser CF, Novelli V, Lipton S, Narkewicz S. Varicella-like illness caused by live varicella vaccine in children with acute lymphocytic leukemia. Pediatrics. 1987;79:922-7.
101. Spingarn RW, Benjamin JA. Universal vaccination against varicella [Letter]. N Engl J Med. 1998;338:683.
102. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol. 1994;140:81-104.
103. Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis. 1996; 173:450-3.
104. Levin MJ, Hayward AR. The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am. 1996;10:657-75.